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Background
Co-infections can compromise empirical therapy when treating genital discharge syndrome (GDS). In the UK, lack
of testing for Mycoplasma genitalium (MG), a common cause of GDS, is particularly challenging because of
increasing rates of macrolide antimicrobial resistance (AMR). We calculated prevalence of MG co-infections,
macrolide resistance and associated risk factors in a diverse symptomatic sexual health clinic (SHC) population.
 
Methods
SHC attendees in England aged ≥16 years, symptomatic of an STI provided: vulvovaginal swabs (females), ﬁrst
void urine (men-who-have-sex-with-women (MSW) and men-who-have-sex-with-men (MSM)), pharyngeal and
rectal swabs (MSM). Routine clinic Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) results were obtained
and PCR used for MG detection. Macrolide resistance was determined using Sanger sequencing. Unadjusted and
risk factor adjusted odds ratios (ORs) for being MG resistant were derived using logistic regression models.
 
Results
Prevalence of MG was 9.5% across all groups and 6.5%(95%CI:4.6-8.9), 12.8%(9.1-17.3) and 12.3%(8.5-17.1) in
females, MSW and MSM, respectively (p<0.005). Among patients infected with CT and/or NG, co-infection with
MG was 18.7%(8.9-32.6), 9.5%(3.6-19.6) and 4.9%(1.4-12.2), respectively (p<0.05). Among MG positives,
macrolide resistance was 62.1%(42.3-79.3), 77.4%(58.9-90.4), and 90.9%(70.8-98.9), respectively. In univariate
analysis, being MSM (OR:3.0[95%CI:1.60-5.88]), being of black (3.02[1.66-5.47]) compared to white ethnicity,
reported more than one regular partner (3.19[1.25-8.13]), having an STI co-infection (10.13[4.62-22.25];p<0.001)
and a recent STI diagnosis (2.09[1.18-3.68];p<0.005) were associated with having macrolide resistant MG. In
multivariable analysis, being MSM (aOR:3.31[1.44-7.61]), being of black ethnicity (3.31[95%CI:1.58-6.94];p<0.005),
more than one regular partner (3.32[1.21-9.08];p<0.005) and having a co-infection (10.35[4. 32-25.30];p<0.001)
remained signiﬁcant.
 
Conclusion
Having an STI co-infection with MG was the strongest indicator of likelihood of having macrolide resistance which
was also associated with being in particular risk groups. These ﬁndings are suggestive that macrolide resistance
may be maintained in discreet sexual networks that are themselves exposed to antibiotic selection pressures.
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